Tredegar Corporation 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Tredegar Corporation for the period ended June 30, 2003. The company operates primarily in three segments: Film Products, Aluminum Extrusions, and Therics (biotechnology). The reporting period is significantly impacted by the divestiture of its venture capital investment portfolio and the suspension of efforts to sell its Therics subsidiary.
Key Financial Metrics
| Metric | Q2 2003 | Q2 2002 | 6 Months 2003 | 6 Months 2002 |
|---|---|---|---|---|
| Revenues (Sales) | $181.6M | $200.6M | $363.6M | $378.0M |
| Net Income (Loss) | $2.6M | ($3.3M) | ($42.1M) | ($2.8M) |
| Income from Continuing Ops | $1.7M | $14.3M | $6.5M | $24.3M |
| Discontinued Ops (Loss) | $0.9M | ($17.6M) | ($48.6M) | ($27.1M) |
| Diluted EPS (Net) | $0.06 | ($0.09) | ($1.09) | ($0.07) |
| Cash from Operations | N/A | N/A | $47.4M | $27.8M |
| Total Debt | $230.1M | N/A | $230.1M | N/A |
| Cash & Equivalents | $113.1M | N/A | $113.1M | N/A |
Note: Debt figures represent outstanding balances at June 30, 2003 ($225M term loan + $5.1M other). Cash flow data is provided for the six-month period only.
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 9.5% in Q2 and 3.8% year-to-date compared to 2002, driven by lower volumes in both Film Products and Aluminum Extrusions.
- Margin Compression: Gross profit margins fell to 15% in Q2 2003 from 21.2% in Q2 2002. This was caused by higher raw material costs (resin, aluminum), energy costs, and the loss of high-margin domestic backsheet business with P&G.
- Discontinued Operations: The six-month net loss of $42.1M is primarily due to a $49.2M after-tax loss on the sale of the venture capital investment portfolio. Excluding this, continuing operations generated a profit of $6.5M.
- Restructuring Charges: The company incurred $5.9M in charges for plant shutdowns, asset impairments, and restructurings in the first six months of 2003, compared to $1.3M in the prior year period.
- Debt Reduction: Total debt decreased, with a net decrease in borrowings of $29.2M during the first six months of 2003.
Outlook, Risks, and Management Commentary
- Guidance Revision: Management announced on June 16, 2003, that it would not achieve the expected $12M ongoing operating profit level in Film Products for Q2 due to higher costs and lower volumes.
- Therics Strategy: Efforts to sell the Therics biotech subsidiary were suspended in April 2003 pending a reassessment of strategic options. The company expects to continue incurring losses from Therics operations.
- Capital Allocation: The company repurchased 406,400 shares of common stock for $5.2M in the first six months. Capital expenditures increased to $26.1M, focused on capacity expansion in the Netherlands and China.
- Key Risks:
- Customer Concentration: Film Products relies heavily on P&G (33% of net sales in 2002).
- Commodity Volatility: Margins are sensitive to polyethylene, polypropylene, and aluminum prices, with no assurance costs can be passed to customers.
- Currency: Appreciation of the Canadian Dollar negatively impacts Aluminum Extrusions profitability.
Investor Verification Checklist
- Discontinued Ops Impact: Verify the sustainability of earnings by excluding the one-time $49.2M loss from the venture capital portfolio sale.
- P&G Exposure: Assess the long-term impact of the loss of domestic backsheet business with P&G on Film Products' volume and margin recovery.
- Therics Future: Monitor the outcome of the strategic reassessment for Therics, as continued losses are expected if a sale is not completed.
- Cost Pass-Through: Evaluate the company's ability to offset rising raw material and energy costs through price increases in a competitive market.
- Tax Recovery Timing: Confirm the expected receipt of $54.4M in income tax recoveries in mid-2004 related to the venture capital sale.